Skip to main content
SpringerLink
Log in

Considerations for HAV vaccine in India

  • Symposium: Tropical Pediatrics—Part I
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Currently available evidence indicates that most parts of India still qualify to be hyper-endemic regions and hence recommendations for vaccinations developed for low endemicity regions are not applicable.

There are however, some pockets which showed evidence of distinct epidemiologic shift. There is need to identify geographic regions like Kerala which have potential for epidemic outbreaks through cyclic sero-epidemiological surveys. With economic development and consequent improvements in the levels of sanitation and quality of water supplies, more such areas will be identified.

Efforts to improve sanitation and personal hygiene will remain as the most important and efficient intervention to retard the transmission of HAV. Unless a critical improvement in the living standards of our population is achieved, aim of eradicating HAV infection from the community is not realistic.

Presently, the cost of three doses of HAV is exorbitant and the focus of HAV vaccination will have to be restricted to individual protection who are likely to remain unexposed till adulthood and can afford to pay for it. HAV infection below 5 years is mostly asymptomatic. The most efficient use of resources will therefore be to offer HAV vaccine to high risk individuals beyond this age after screening for antibodies against HAV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Editorial: The A to F of viral hepatitis.Lancet 1990; 336: 1158–1160.

  2. Margolis HS, Alter MJ. Will hepatitis A become a vaccine-preventable disease?Ann Intern Med 1995; 122: 465–466.

    Google Scholar 

  3. Hadler SC, Webster HM, Erben JJet al. Hepatitis A in day care centres. A community—wide assesment.N Engl J Med 1980; 302: 1222–1227.

    Article  PubMed  CAS  Google Scholar 

  4. Lednar WM, Lemon SM, Kirckpatrick JWet al. Frequency of illness associated with epidemic hepatitis A virus infections in adults.Am J Epidemiol 1985; 122: 226–233.

    PubMed  CAS  Google Scholar 

  5. Forbes A, Williams R. Increasing age—an important adverse prognostic factor in hepatitis A virus infection.J Royal Coll Phy London 1988; 22 (4): 237–239.

    CAS  Google Scholar 

  6. Tong MJ, El-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital.J Infect Dis 1995; 171 (suppl 1): S15-S18.

    PubMed  Google Scholar 

  7. Committee on Infectious Diseases, American Academy of Pediatrics. Prevention of Hepatitis A Infections. Guidelines for use of hepatitis A vaccine and Immune Globulin.Pediatrics 1996; 98 (6): 1207–1215.

    Google Scholar 

  8. Yao G. Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic. In: Hollinger FB, Lemon SM, Margolis H (eds)Viral Hepatitis and Liver Disease: Proceedings of the 1990 International symposium. Baltimore, MD: Williams and Wilkins, 1991; 76–80.

    Google Scholar 

  9. Hadler SC. Global impact of hepatitis A virus infection: Changing patterns. In: Hollinger FB, Lemon SM, Margolis H (eds).Viral Hepatitis and Liver Disease: Proceedings of the 1990 International Symposium. Baltimore, MD: Williams and Wilkins, 1991; 14–20.

    Google Scholar 

  10. Keeffe EB. Is Hepatitis A more severe in patients with Chronic Hepatitis B and Other Chronic Liver Disease?Am J Gastroenterol 1995; 90 (2): 201–205.

    PubMed  CAS  Google Scholar 

  11. Provost PJ, Hilleman MR. Propagation of human hepatitis A virus in cell culture.Proc Soc Exp Biol Med 1979; 160: 213–221.

    PubMed  CAS  Google Scholar 

  12. Andre FE. Development of a vaccine against hepatitis A. In: Hollinger FB, Lemon SM, Margolis HS (eds):Viral hepatitis and Liver Disease. Baltimore; Williams and Wilkins 1991; 85–88.

    Google Scholar 

  13. Jilg W, Bittner R, Schatzl H, Raßhofer R, Schmidt M, Deinhardt F. The immune response to different doses of inactivated hepatitis A vaccine.J Hepatol 1993; 18 (2): S38-S40.

    Article  PubMed  Google Scholar 

  14. Carlsson RM, Claesson BA, Iwarson SA. Dose response study of an inactivated hepatitis A virus vaccine.J Hepatol 1993; 18 (2): S41-S45.

    Article  PubMed  Google Scholar 

  15. Tilzey AJ, Palmer SJ, Barrow Set al. Effect of hepatitis A vaccination schedules on immune response.Vaccine 1992; 10: S121-S123.

    Article  PubMed  Google Scholar 

  16. Nalin DR, Lewis JA, Calandra GBet al. Worldwide experience with inactivated hepatitis A virus vaccine in pediatric and adult population.J Hepatol 1993; 18 (Suppl 2): S51-S55.

    Article  PubMed  Google Scholar 

  17. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated Hepatitis A vaccine.J Infect Dis 1995; 171 (suppl 1): S44-S49.

    PubMed  Google Scholar 

  18. Hondt DT, Purcell RH. Emerson SU, Wong DC, Shapiro M, Govindarajan S. Efficacy of an inactivated hepatitis A vaccine in pre and postexposure conditions in Marmosets.J Infect Dis 1995; 171 (suppl 1): S40–43.

    PubMed  Google Scholar 

  19. Leentvaar-Kuijpers A, Coutinho RA, Brulein V, Safary A. Simultaneous passive and active immunizations against hepatitis A.Vaccine 1992; 10: S138-S145.

    Article  PubMed  Google Scholar 

  20. Lemon SM. Immunologic approaches to assessing the response to inactivated hepatitis A vaccine.J Heptol 1993; 18 (suppl 2): S15-S19.

    Article  Google Scholar 

  21. Midthun K, Ellerbeck E, Gershman Ket al. Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers.J Infect Dis 1991; 163: 735–739.

    PubMed  CAS  Google Scholar 

  22. VanDamme P, Thoelen S, Gramm Met al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity and long term antibody persistence.J Med Virol 1994 (Suppl).

  23. Meinick JL. History and Epidemiology of Hepatitis A virus.J Infect Dis 1995; 171 (suppl 1): S2-S8.

    Google Scholar 

  24. Shapiro CN, Margolis HS. Worldwide epidemiology of hepatitis A virus infection.J Hepatol 1993; 18 (Suppl 2): S11-S14.

    Article  PubMed  Google Scholar 

  25. Amela C, Pachon I, Bueno R, Miguel de C, Navarro MF. Trends in hepatitis A virus infection with reference to the process of urbanization in the greater Madrid area (Spain).Eur J Epidemiol 1995; 11: 569–573.

    Article  PubMed  CAS  Google Scholar 

  26. Kremastinou J, Kalapothaki V, Trichopoulos D. The changing epidemiologic pattern of hepatitis A infection in urban Greece.Am J Epidemiol 1984; 120 (5): 703–706.

    PubMed  CAS  Google Scholar 

  27. Schwartz Eli, Raveh D. The prevalence of hepatitis A antibodies among Israeli travelers and the economic feasibility of screening before vaccination.Int J Epidemiol 1998; 27: 118–120.

    Article  Google Scholar 

  28. Furusyo N, Hayashi J, Sawagama Y, Kawakami Y, Kishihara Y, Kashiwagi S. The elimination of hapatitis B virus infection: Changing seroepidemiology of hepatitis A and B virus infection in Okinawa, Japan over a 26-year period.Am J Trop Med Hyg 1998; 59 (5): 693–698.

    PubMed  CAS  Google Scholar 

  29. Shaw FE, Halder SC Jr., Maynard JE. Hepatitis A in Mauritius: an apparent transition from endemic to epidemic transmission patterns.Ann Trop Med Parasito 1989; 83 (2): 179–185.

    Google Scholar 

  30. Tandon BN, Gandhi BM, Joshi YK. Aetiological spectrum of viral hepatitis and prevalence of markers of hepatitis A and B virus infection in North India.WHO Bull 1984; 62 (1): 67–73.

    CAS  Google Scholar 

  31. Wernes GT, Froznes GG, Sareen SK. Prevalence of hepatitis A and B and HIV markers in Punjab.JIMA 1990; 88: 293–294.

    Article  Google Scholar 

  32. Arankalle VA, Tsarev SA, Chadha MS, Alling DW, Emerson SU, Banerjee Ket al. Age specific prevalence of antibodies to hepatitis A and E viruses in Pune, India. 1982 and 1992.J Infect Dis 1995; 171 (2): 447–450.

    PubMed  CAS  Google Scholar 

  33. Dhawan PS, Shah SS, Alvares JF, Kher A, Shankaran K, Kandoth PWet al. Seroprevalence of hepatitis A virus in Mumbai, and immunogenicity and safety of hepatitis A vaccine.Ind J Gastroenterol 1998; 17: 16–18.

    CAS  Google Scholar 

  34. Dutta AK, Aggarwal A, Kapoor AK, Ray GN, Batra S. Seroepidemiology of hepatitis A in children in Delhi.Ind J Ped 1999 (in press).

  35. Mittal SK, Rastogi A, Rastogi A, Kumar N, Talukdar B, Kar P. Seroprevalence of Hepatitis A in children-implications for hepatitis A vaccine.Trop Gastroenterol 1998; 19: 120–121.

    PubMed  CAS  Google Scholar 

  36. Mathew P, Bobba R, Zacharias Pet al. Hepatitis A seroprevalence in Kerala.Ind J Gastroenterol 1998; 17 (1): S71-S72.

    Google Scholar 

  37. Thakur V, Guptan RC, Bagga S, Safary A, Sarin SK. Prevalence of hepatitis A antibodies in children in India. Proceedings of the 39th Annual. Conference of the Indian Society of Gastroenterology.Ind J Gastroenterol 1998; 17 (1): S67.

    Google Scholar 

  38. Singh J, Prakash C, Gupta RS, Bora D, Jain DC, Datta KK. Epidemiology of endemic viral hepatitis in an urban area of India: a retrospective community study in Alwar.Bull WHO 1997; 75 (5): 463–468.

    PubMed  CAS  Google Scholar 

  39. Sebastain B, Mathai S, Mathew G, Ouseph M. Balakrishnan. An outbreak of hepatitis A in central Kerala—clinical profile. Proceedings of the 39th Annual. Conference of the Indian Society of Gastroenterology.Ind J Gastroenterol 1998; 17 (1): S10.

    Google Scholar 

  40. Stapleton JT. Lange DK, LeDuc JW, Binn LN, Jansen RW, Lemon SM. The role of secretory immunity in hepatitis A virus infection.J Infect Dis 1991; 163: 7–11.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Paediatric Gastroenterology, Hapatology and Nutrition, Dapartment of Pediatrics, AIIMS, 110 029, New Delhi

    Prashant Mathur & Narendra K. Arora

Authors
  1. Prashant Mathur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Narendra K. Arora
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mathur, P., Arora, N.K. Considerations for HAV vaccine in India. Indian J Pediatr 66, 111–120 (1999). https://doi.org/10.1007/BF02752368

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02752368

Key words

Search

Navigation